🇺🇸 FDA
Patent

US 9254338

Use of a VEGF antagonist to treat angiogenic eye disorders

granted A61KA61K2039/505A61K38/179

Quick answer

US patent 9254338 (Use of a VEGF antagonist to treat angiogenic eye disorders) held by REGENERON PHARMACEUTICALS, INC. expires Mon Feb 04 2036 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
REGENERON PHARMACEUTICALS, INC.
Grant date
Tue Feb 09 2016 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Feb 04 2036 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
26
CPC classes
A61K, A61K2039/505, A61K38/179, A61K9/0048, A61P